<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194555</url>
  </required_header>
  <id_info>
    <org_study_id>ANODYNE-3</org_study_id>
    <nct_id>NCT03194555</nct_id>
  </id_info>
  <brief_title>The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination</brief_title>
  <official_title>Randomized, Double-Blind, Study to Assess Low-Dose Naltrexone and Acetaminophen Combination in the Prevention of Episodic Migraine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allodynic Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allodynic Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination:&#xD;
      A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label&#xD;
      Extension for None-Responders&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Actual">July 28, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean number of migraine/probable migraine headache days.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the 12-week treatment period.</time_frame>
    <description>(Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version).&#xD;
Probable migraine, is defined according to the ICHD - 3 (beta version) criteria, as attacks fulfilling all but one of criteria A-D for migraine with or without aura, where criteria B is headache attacks lasting 4-72 hours (untreated or unsuccessfully treated).&#xD;
Migraine/probable migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of headache days.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the 12-week treatment period.</time_frame>
    <description>(Headache days are defined as none-migraine headache days plus migraine headache days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 50% or more reduction in migraine/probable migraine headache days.</measure>
    <time_frame>From the28-day baseline period to the last 28 days of the12-week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean migraine severity.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the 12-week treatment period.</time_frame>
    <description>(Measured on the 4-point (0-3) rating scale, (0=none, 1=mild, 2=moderate, 3=severe)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean migraine duration.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the12-week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean nausea severity.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the12-week treatment period.</time_frame>
    <description>(Measured on the 4-point (0-3) rating scale, (0=none, 1=mild, 2=moderate, 3=severe)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of acute migraine medications intake days.</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the 12-week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients &quot;satisfied&quot; or &quot;extremely satisfied&quot; with migraine prevention.</measure>
    <time_frame>Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean migraine disability assessment scale (MIDAS)</measure>
    <time_frame>From baseline to week 12 of the treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean headache impact test (HIT-6).</measure>
    <time_frame>From the 28-day baseline period to the last 28 days of the 12-week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean Pittsburgh Insomnia Rating Scale-20 (PIRS-20).</measure>
    <time_frame>From baseline to week 12 of the treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of patients who experienced adverse events.</measure>
    <time_frame>A 12-week treatment period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Migraine With or Without Aura</condition>
  <arm_group>
    <arm_group_label>Low-Dose Naltrexone and Acetaminophen Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-Dose Naltrexone and Acetaminophen Combination</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>Low-Dose Naltrexone and Acetaminophen Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is a male or a female 18 years of age or older.&#xD;
&#xD;
          2. History of migraine with or without aura according to the International Classification&#xD;
             of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with&#xD;
             onset of migraine prior to 50 years of age.&#xD;
&#xD;
          3. Migraine-associated nausea with ≥half of migraine attacks.&#xD;
&#xD;
          4. 5-8 migraine/probable migraine headache days on average per month in the three months&#xD;
             prior to Visit 1 and during the Baseline Period.&#xD;
&#xD;
          5. The patient agrees to refrain from taking opiate medications from Visit 1 to 7 days&#xD;
             after the last dose of the study drug.&#xD;
&#xD;
          6. The patient is able to complete study questionnaires, comply with the study&#xD;
             requirements and restrictions, and willing to provide written informed consent and&#xD;
             authorize HIPAA.&#xD;
&#xD;
          7. The patient has been taking a stable dose of a medication with migraine prevention&#xD;
             potential for at least 3 month prior to the screening visit and agrees to not start,&#xD;
             stop, or change dosage of any medication with migraine prevention potential during the&#xD;
             study period. (E.g., beta-blockers, calcium channel blockers, tricyclic&#xD;
             antidepressants, anticonvulsants, selective serotonin re-uptake inhibitors (SSRIs),&#xD;
             serotonin-norepinephrine re-uptake inhibitors (SNRIs), magnesium or riboflavin&#xD;
             supplements at high doses, herbal preparations (e.g. feverfew or St. john's wort)),&#xD;
             Botulinum toxin must be discontinued one year prior to Visit 1.&#xD;
&#xD;
          8. The patient agrees to forgo any elective surgery for the duration of the study.&#xD;
&#xD;
          9. The female patient who is premenopausal or postmenopausal less than 1 year, or have&#xD;
             not had surgical sterilization (i.e., tubal ligation, partial or complete&#xD;
             hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit&#xD;
             to using 2 methods of adequate and reliable contraception throughout the study and for&#xD;
             28 days after taking the last dose of the study drug (e.g., barrier with additional&#xD;
             spermicidal, intra-uterine device, hormonal contraception). Male patients must be&#xD;
             surgically sterile or commit to the use of 2 different methods of birth control during&#xD;
             the study and for 28 days after the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Usage of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) ≥15&#xD;
             days/month, or ergotamine and triptans &gt;10 days/month, or opioids and barbiturates &gt;2&#xD;
             days/month in the 3 months prior to Visit 1 or during the Baseline Period.&#xD;
&#xD;
          2. Tension-type-like, and/or migraine-like headache on ≥15 days per month in the 3 months&#xD;
             prior to Visit 1 or during the Baseline Period. Diagnosis of chronic migraine, cluster&#xD;
             headache or neurologically complicated migraine (hemiplegic, basilar, retinal,&#xD;
             ophthalmoplegic migraine).&#xD;
&#xD;
          3. Regular use of the following medications for any reason: acetaminophen, non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs), antipsychotic drugs, monoamine oxidase inhibitors,&#xD;
             benzodiazepines, sleep medications, muscle relaxants, anti-emetic medications, blood&#xD;
             thinning medications (e.g., warfarin or heparin), cannabinoids, or botulinum toxin to&#xD;
             head and neck regions. Low-dose aspirin for cardiovascular disease prophylaxis is&#xD;
             permitted.&#xD;
&#xD;
          4. Confounding painful conditions, (e.g. fibromyalgia, chronic low back pain, complex&#xD;
             regional pain syndrome, etc.).&#xD;
&#xD;
          5. Diagnosis of any concurrent medical or psychiatric condition; this includes, chronic&#xD;
             unstable debilitating diseases such as Parkinson's disease, multiple sclerosis,&#xD;
             cancer, significant renal impairment, significant hepatic impairment, etc.&#xD;
&#xD;
          6. The patient has a history or diagnosis of moderate-to-severe hepatic or renal&#xD;
             impairment (&gt;2 × the upper limit of normal [ULN] for alanine transaminase or aspartate&#xD;
             transaminase. ≥1.5 × ULN for alkaline Phosphatase, bilirubin, BUN, or creatinine).&#xD;
             (Patients with elevated bilirubin level due to Gilbert's syndrome are allowed).&#xD;
&#xD;
          7. The patient has a history within the previous 5 years of abuse of any drug,&#xD;
             prescription, illicit, or alcohol.&#xD;
&#xD;
          8. The Female patient is pregnant, actively trying to become pregnant, or breast-feeding.&#xD;
             The Male patient is not practicing 2 different methods of birth control with their&#xD;
             partner during the study, and for 28 days after the investigational drug last dose or&#xD;
             will not remain abstinent during the study, and for 28 days after the last dose.&#xD;
&#xD;
          9. The patient has known-allergy to any of the components of the investigational drug.&#xD;
&#xD;
         10. Participation in another study with an investigational drug within 30 days before&#xD;
             Visit 1 or during the study.&#xD;
&#xD;
         11. Use of emergency care treatment more than 3 times in the previous 6 months.&#xD;
&#xD;
         12. The patient is in the opinion of the investigator, is unsuitable to participate in&#xD;
             this study for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Toledano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allodynic Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annette Toledano, M.D.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Innate Immune System</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Cox-2</keyword>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Migraine Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

